Literature DB >> 18718118

Distribution of an intravenous injectable nimodipine nanosuspension in mice.

Ruolan Xiong1, Weigen Lu, Peng Yue, Rong Xu, Jun Li, Tingting Chen, Peiquan Wang.   

Abstract

The distribution of an intravenous injectable nimodipine nanosuspension with mean particle size of both 300 and 650 nm in mice was systemically investigated compared with that of a nimodipine ethanol formulation (Nimotop) and a nanosuspension coated with Tween-80. The results showed that the 650-nm nanoparticles provided significantly higher drug concentrations in the liver, spleen and lungs because of their capture by Kupffer cells in the mononuclear phagocyte system, but lower drug concentrations in the brain compared with Nimotop and smaller nanoparticles. These nanoparticles failed to give increased brain concentrations even when coated with Tween-80. The 300-nm nanoparticles could effectively increase drug concentrations in the brain and remarkably reduce drug concentrations in the liver, spleen and lungs, indicating that the nimodipine nanosuspension may be a promising formulation with no ethanol, but the particle size must be small.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718118     DOI: 10.1211/jpp.60.9.0006

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112.

Authors:  Dong Dong; Xiao Wang; Huailing Wang; Xingwang Zhang; Yifei Wang; Baojian Wu
Journal:  Int J Nanomedicine       Date:  2015-03-31

2.  The effect of surface treatment on the brain delivery of curcumin nanosuspension: in vitro and in vivo studies.

Authors:  Maryam Dibaei; Mohammad-Reza Rouini; Behjat Sheikholeslami; Mahdi Gholami; Rassoul Dinarvand
Journal:  Int J Nanomedicine       Date:  2019-07-19

Review 3.  Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications.

Authors:  Eknath Ahire; Shreya Thakkar; Mahesh Darshanwad; Manju Misra
Journal:  Acta Pharm Sin B       Date:  2018-07-26       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.